OTHER GROUP COMPANIES
market

Aurobindo Pharma gets six observations from USFDA for Unit VII; Stock sheds 2%

The Company will respond to the US FDA within the stipulated timeline.

May 11, 2022 9:22 IST | India Infoline News Service
The United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma Ltd's Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, from May 02-10, 2022.

"At the end of the inspection, we have been issued a ‘Form 483’ with six observations", said pharma major in a regulatory filing on Tuesday.

Further, the Company will respond to the US FDA within the stipulated timeline and work closely with US FDA to close the observations.

At around 9:22 AM, Aurobindo Pharma was trading at Rs591.15 per piece lower by 1.97% on the BSE.

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000

FEATURED ARTICLE

BLOGS

Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity